Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib in BRCA1/2-mutated high-grade serous ovarian cancer or ovarian carcinosarcoma after progression
ACTRN12619000583145Phase 2Withdrawn
- Sponsor
- Australia New Zealand Gynaecological Oncology Group
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pamiparib in ovarian cancer and carcinosarcoma (2 cohorts), sponsored by Australia New Zealand Gynaecological Oncology Group. Primary endpoint: Clinical benefit rate. Planned start Aug 2019; status: withdrawn.
02
Drugs
pamiparib
03
Conditions
ovarian cancercarcinosarcoma
Beyond the preview
Go deeper on ACTRN12619000583145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000583145.